News | Stents | July 05, 2022

Favorable Outcomes for Orsiro DES presented at EuroPCR in the Five-Year BIO-RESORT Small Vessels Subgroup Analysis

BIO-RESORT: TLF at five years

BIO-RESORT: TLF at five years 


July 5, 2022 — A BIO-RESORT subgroup analysis of outcomes in small coronary vessels (<2,5mm) evaluated the efficacy and safety of three contemporary DES including BIOTRONIK’s ultrathin struts drug-eluting stent (DES) Orsiro at 5 years. The results of the analysis were presented by Dr. Eline H. Ploumen, Thoraxcentrum Twente, Medisch Spectrum Twente, Enschede, The Netherlands, at the EuroPCR conference in May.   

Patients with smaller coronary target vessels are usually associated with a higher risk of Target Lesion Revascularization (TLR) following percutaneous coronary intervention (PCI)1. In this context, the BIO-RESORT subgroup analysis aimed to assess whether thinner struts lead to a lower adverse event risk and better patient outcomes. The randomized trial analyzed the five-year outcomes of coronary artery disease patients treated with three contemporary DES of varying strut-thickness – ultrathin (Orsiro), very thin (Synergy) and thin (Resolute Integrity) strut drug-eluting stents.2 

"Although we have not seen a statistically significant difference in five-year target lesion failure rate, our subgroup-analysis shows a trend towards better outcomes with thinner strut DES for patients with small vessels", commented Dr. Eline H. Ploumen on the results. "While percutaneous coronary intervention of small vessel lesions remains challenging, thinner strut DES are a good choice for the treatment of these lesions." 

Key findings: 

Although patients treated with Orsiro DES were more often treated for a complex target lesion than patients with other DES (71.4% for Orsiro vs. 68.7% for Synergy and 63.3% for Resolute Integrity), results show favorable outcomes for BIOTRONIK’s ultrathin strut DES. 

Target lesion failure (TLF) for Orsiro DES remains numerically lower at 5 years (10.5% for Orsiro vs. 11.1% for Synergy and 12.6% for Resolute Integrity). 

Target lesion revascularization (TLR) for Orsiro DES remains numerically lower at 5 years (4.4% for Orsiro vs. 4.7% for Synergy and 6.8%% for Resolute Integrity). 

Definite or probable stent thrombosis rate remains numerically lower for Orsiro DES at 5 years (1.0% for Orsiro vs. 1.7% for Synergy and 2.0% for Resolute Integrity). 

"These new BIO-RESORT data support the benefits of our outstanding Orsiro DES design", noted Dr. Alexander Uhl, President Vascular Intervention at BIOTRONIK. "Small vessels are a particularly challenging lesion type to treat and with Orsiro the data indicates we can achieve an incremental improvement in patient outcomes."   

The BIO-RESORT non-inferiority study included 3,514 all-comer patients and was designed to assess two biodegradable polymer stents against a durable polymer reference device in all-comers patients. At one-year, non-inferiority was established for Orsiro and Synergy against Resolute Integrity DES3. Last year, full-cohort five-year outcomes from the BIO-RESORT trial were presented at the Transcatheter Cardiovascular Therapeutics (TCT) conference.4 

References: 

1. Wykrzykowska J. J. et al.: Impact of vessel size on angiographic and clinical outcomes of revascularization with biolimus-eluting stent with biodegradable polymer and sirolimus-eluting stent with durable polymer: The LEADERS trial substudy. JACC Cardiovasc Interv. 2009 Sep;2(9):861-70. 

2. Strut thickness: Orsiro 60 μm, Synergy 74 μm and Resolute Integrity 91 μm. 

3. von Birgelen C. et al.: Very thin strut biodegradable polymer everolimus-eluting and sirolimus-eluting stents versus durable polymer zotarolimus-eluting stents in allcomers with coronary artery disease (BIO-RESORT): a three-arm, randomised, non-inferiority trial, The Lancet, 2016 Nov 26;388(10060):2607-17. 

4. Ploumen E.H., BIO-RESORT : 5 Year outcomes from a randomized trial of 3 drug- eluting stents in patients with coronary artery disease, presented at TCT 2021

Orsiro is a trademark or registered trademark of the BIOTRONIK Group of Companies. All other brands are trademarks are the property of their respective owners. 

For more information: https://en.orsiro.com/ 

Related Stent Content: 

New Directions and Trends in Coronary Metallic Stents 

Biotronik's Orsiro Drug-Eluting Stent Outperforms Xience in BIOFLOW-V Trial 

Orsiro Stent Performs in Two Comparison Studies Presented at TCT 2018 

Orsiro DES Shows Lowest Two-Year Target Lesion Failure in BIO-RESORT Trial 

Orsiro Demonstrates Benefit over Xience in Heart Attack Subgroup 

Biotronik Orsiro DES Shows Low Five-Year Event Rates 

Biotronik Orsiro Hybrid Drug-Eluting Stent Lives up to Abbott’s Xience Prime Standards 

Independent Study Finds Biodegradable Polymer Stents Provide No Clinical Benefit Over Resolute Integrity DES 

VIDEO: The Current State of Bioresorbable Stents in 2018 — Interview with Patrick Serruys, M.D. 

VIDEO: Cath Lab of the Future Cardiovascular Technologies to Watch — Interview with Juan Granada, M.D. 

Related Content

News | TCT

August 4, 2022 — The Cardiovascular Research Foundation (CRF) has announced the late-breaking clinical science that will ...

Home August 04, 2022
Home
News | TCT

August 2, 2022 — Two significant awards will be presented at TCT 2022, to be held in Boston, Sept. 16-19, 2022. Career ...

Home August 02, 2022
Home
News | TCT

July 12, 2022 — The Cardiovascular Research Foundation (CRF) and Fogarty Innovation announced today that they are ...

Home July 12, 2022
Home
Feature | TCT

November 10, 2021 — There were nine late-breaking trials and 13 late-breaking science presentations at the 2021 ...

Home November 10, 2021
Home
Feature | TCT | Dave Fornell, Editor

Here are some of the key takeaways from the late-breaking interventional cardiology and structural heart trials ...

Home October 29, 2020
Home
Feature | TCT

October 15, 2020 — The late-breaking studies are one of the hallmarks of the annual Transcatheter Cardiovascular ...

Home October 15, 2020
Home
News | TCT

October 14, 2020 — The American College of Cardiology (ACC) and the Cardiovascular Research Foundation (CRF) are ...

Home October 14, 2020
Home
Videos | TCT

With COVID-19 forcing all medical conferences to go virtual in 2020, Juan F. Granada, M.D., CEO of the Cardiovascular ...

Home August 01, 2020
Home
Feature | TCT | Dave Fornell, Editor

The latest in interventional cardiology clinical data and new device technologies were highlighted at the annual ...

Home November 04, 2019
Home
Feature | TCT

October 10, 2019 — Here are the Cardiovascular Research Foundation (CRF) 12 late-breaking trials and 16 late-breaking ...

Home October 11, 2019
Home
Subscribe Now